Clinical Trial

Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This trial is to evaluate the safety and efficacy of ficerafusp alfa in combination with pembrolizumab prior to surgical resection in participants with resectable, high-risk, locoregionally advanced, PD-L1-positive squamous cell carcinoma of the head and neck (HNSCC). The names of the study drugs used in this research study are: * ficerafusp alfa (a type of bifunctional antibody and recombinant fusion protein) * pembrolizumab (a type of monoclonal antibody)
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-06.
Status change: Not Yet Recruiting → Recruiting 2026-03-26
Trial Details
NCT Number NCT07465276
Lead Sponsor Dana-Farber Cancer Institute
Collaborators: Bicara Therapeutics
Conditions Head and Neck Squamous Cell Carcinoma (HNSCC), Squamous Cell Carcinoma of the Head and Neck
Enrollment 32 participants
Start Date 2026-03-26
Primary Completion 2028-04-30 (estimated)
Study Completion 2030-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-27